Hotspots and development trends of gut microbiota in atopic dermatitis: A bibliometric analysis from 1988 to 2024 DOI Creative Commons
Fang Liu, Haipeng Zhang, Lina Fan

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(50), P. e40931 - e40931

Published: Dec. 13, 2024

Background: Atopic dermatitis (AD) is a prevalent inflammatory skin condition that commonly occurs in children. More and more scientific evidence suggests gut microbiota plays an important role the pathogenesis of AD, whereas there no article providing comprehensive summary analysis. We aimed to analyze documents on AD identify hotspots development trends this field. Methods: Articles reviews field from January 1, 1988 October 20, 2024 were obtained Web Science Core Collection database. Biblioshiny was utilized for evaluating visualizing core authors, journals, countries, documents, trend topics, Results: Among 1672 it indicated number annual publications generally increased. The United States had highest production, impact, international collaboration. Journal Allergy Clinical Immunology journal maximum publications. Based keyword co-occurrence clustering analysis, “stratum-corneum lipids,” “probiotics,” “prebiotics,” “fecal transplantation,” “phage therapy,” “short chain fatty-acids,” “biologic “skin inflammation” represented current topics. pathological molecular mechanisms associated therapeutic methods research hotspots. incorporation microbiota-based therapies alongside conventional treatments can contribute better clinical outcomes. Conclusion: highlighted may exacerbate symptoms through various aspects, including immunity, metabolites, neuroendocrine pathways. efforts are required investigate safety efficacy microbial management prevention treatment AD.

Language: Английский

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study DOI Creative Commons
Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

et al.

Journal of Dermatological Treatment, Journal Year: 2024, Volume and Issue: 35(1)

Published: April 23, 2024

Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).

Language: Английский

Citations

14
Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis DOI Creative Commons
Teppei Hagino,

Mai Yoshida,

Risa Hamada

et al.

Journal of Dermatological Treatment, Journal Year: 2024, Volume and Issue: 35(1)

Published: Jan. 31, 2024

Background Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors high responders to have not been established in real-world clinical practice.

Language: Английский

Citations

13
Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks DOI Creative Commons
Teppei Hagino,

Risa Hamada,

Mai Yoshida

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 30, 2024

Atopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced cytokines dependent on Janus kinases (JAKs). Upadacitinib, JAK1 inhibitor, effective for moderate-to-severe AD. This study aims to identify biomarkers that reflect long-term therapeutic effects of upadacitinib 15 mg or 30 mg. A retrospective from August 2021 July 2023 included 213 AD patients treated with 70 We analyzed eczema area severity index (EASI), peak pruritus-numerical rating scale (PP-NRS), serum immunoglobulin E (IgE), thymus activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), total eosinophil count (TEC) at weeks 0, 4, 12, 24, 36, 48 treatment. Both treatments reduced EASI PP-NRS scores over week 4 compared baseline. Upadacitinib treatment decreased TEC baseline through 36 48, respectively. The percent reduction correlated those mg, 12 After adjusting % reductions other laboratory markers, the significance correlations was preserved treatment, while during indicating its potential as biomarker reflecting responses in patients. However, variability significant correlation indicates further inspection needed usefulness monitoring

Language: Английский

Citations

12
Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan DOI
Teppei Hagino, Akihiko Uchiyama,

Marina Onda

et al.

Dermatitis, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Abstract: Background: Real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited.

Language: Английский

Citations

1
Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis DOI Creative Commons
Teppei Hagino,

Risa Hamada,

Mai Yoshida

et al.

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2023, Volume and Issue: Volume 16, P. 3201 - 3212

Published: Nov. 1, 2023

To investigate the therapeutic effectiveness and safety of Janus kinase 1 inhibitor upadacitinib in adolescent patients with atopic dermatitis (AD).This study examined for 39 Japanese (aged 12-17 years) diagnosed moderate-to-severe AD from August 2021 to January 2023. The were treated 15 mg/day plus twice daily topical corticosteroids. Total eczema area severity index (EASI) or EASI on head neck, upper limbs, lower trunk erythema, edema/papulation, excoriation, lichenification, control tool (ADCT), peak pruritus-numerical rating scale (PP-NRS), laboratory indexes assessed at weeks 0, 4, 12 treatment. Treatment-emergent adverse events recorded.Total 4 anatomical sites rash types, ADCT, PP-NRS significantly reduced week compared 0. achievement rates 64.1% 62.5% 75, 93.5% 73.1% ADCT <7-point, 80.6% 60% ≥4-point improvement, respectively, indicating their slight decrease 12. percent reduction excoriation was higher than that lichenification edema/papulation 12, respectively. reductions erythema neck those limbs eosinophil counts (TEC) IgE 0 while TARC, IgE, TEC, LDH increased 4.These results suggest tolerability support its usefulness patients.

Language: Английский

Citations

17
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study DOI Creative Commons
Teppei Hagino,

Risa Hamada,

Mai Yoshida

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(4), P. 519 - 519

Published: April 18, 2024

Clinical trials and real-world studies have shown the effectiveness of upadacitinib for treating rash pruritus in patients with atopic dermatitis (AD). This study aimed to determine whether early reduction or at week 12 treatment could be maintained later stages. retrospective involved 227 73 moderate-to-severe AD treated 15 30 mg daily, respectively. The eczema area severity index (EASI) scores, peak numerical rating scale (PP-NRS), investigator’s global assessment (IGA) were analyzed. At 12, divided into achievers non-achievers EASI 75, 90, 100, absolute ≤ 2, IGA0/1, PP-NRS4, PP-NRS 1. Achievement rates each endpoint assessed time points (weeks 24, 36, 48) both groups. Week largely their achievements until 48, regardless dosage (15 mg). saw an increasing achievement rate 75 48. initial persisted 48 treatment, suggesting potential benefits requiring prolonged despite not achieving 12.

Language: Английский

Citations

6
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan DOI Creative Commons
Teppei Hagino,

Mai Yoshida,

Risa Hamada

et al.

Journal of Dermatological Treatment, Journal Year: 2023, Volume and Issue: 34(1)

Published: Dec. 10, 2023

Background Atopic dermatitis (AD) is a chronic eczematous disease with severe pruritus. Janus kinase (JAK) inhibitors, upadacitinib, baricitinib, and abrocitinib, are systemic treatments for AD. The outcomes of switching from one JAK inhibitor to another have not been examined.

Language: Английский

Citations

14
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice DOI Open Access
Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

et al.

Annals of Dermatology, Journal Year: 2025, Volume and Issue: 37

Published: Jan. 1, 2025

Atopic dermatitis (AD) is a chronic eczematous disorder characterized by intense itchiness. Systemic therapies for AD include Janus kinase (JAK) inhibitors and various biological agents. The effects of transitioning from the JAK1 inhibitor, upadacitinib, to anti-interleukin 13 antibody, tralokinumab, remain unclear. This study evaluated transition 15 mg upadacitinib tralokinumab in patients with moderate-to-severe AD. analysis included 20 who switched due an inadequate response or adverse events (AEs). We assessed total regional eczema area severity index (EASI), which assessments head neck, trunk, upper lower limbs, along erythema, edema/papulation, excoriation, lichenification, peak pruritus numerical-rating scale (PP-NRS), initially (start upadacitinib), at point (week 0), during follow-up weeks 4 12. EASI, EASI four anatomical regions, clinical manifestations significantly declined baseline 12, no substantial reductions week 0. PP-NRS score notably decreased 4. Achieving 50 75 improved post-switching. Transitioning substantially alleviated rash experienced suboptimal responses AEs upadacitinib.

Language: Английский

Citations

0
Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study DOI
Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

et al.

Dermatitis, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 11, 2025

Background: An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD), but its effectiveness on different anatomical sites and clinical signs remains unclear. Objective: To assess the of AD. Methods: This study included 129 moderate-to-severe AD patients treated with 36 weeks. Eczema Area Severity Index (EASI) scores were analyzed four (head/neck, trunk, upper, lower limbs) (erythema, edema/papulation, excoriation, lichenification) at weeks 0, 4, 12, 24, 36. Results: Tralokinumab consistently reduced EASI 4 signs. The magnitude decreasing appeared highest limbs while achievement rates 75 week mostly similar (72.6-77.6%). achieving or 100 erythema, lichenification edema/papulation 71.1%, 69.4%, 68.4%, 60.5%, respectively. Conclusions: across various in patients. These findings suggest that may be widely useful diverse skin manifestations

Language: Английский

Citations

0
Recognizing Dupilumab‐Associated Head and Neck Dermatitis in Skin of Color: A Case Series DOI Creative Commons
Divya M. Shan,

Marisa Riley,

David Micah Milgraum

et al.

Clinical Case Reports, Journal Year: 2025, Volume and Issue: 13(3)

Published: Feb. 26, 2025

ABSTRACT Dupilumab‐associated head and neck dermatitis (HND) is a rare often underrecognized condition, especially in patients with skin of color. It can vary from subtle to severe presentations, violaceous hues seborrheic distribution after dupilumab initiation. Early recognition management are crucial prevent treatment discontinuation.

Language: Английский

Citations

0